Current Events

159. Right-to-Try and Experimental Drugs: What Every Health Professional Needs to Know

Sunday, October 21
10:00 AM - 11:00 AM
CE: 1.0

Session Level 2- Intermediate

In 2018, President Trump signed into law the "Right to Try," which promised to allow patients who had no other treatment options available to be able to access investigational, experimental medicines. But this is only the latest of several pathways by which patients can seek (non-guaranteed) access to investigational treatments. In this session, led by an expert in access to investigational medical products, you will learn about the three primary routes by which patients with no other options may access experimental, unapproved medicines. The pros and cons of each of these routes will be reviewed and what members of the health care team ought to be aware of for each will be discussed. The session will be framed from the perspective of what information and issues healthcare providers should be aware of when dealing with patients who are taking, or seeking, access to investigational, unapproved medicines. The presentation will draw upon case studies and will include ample opportunity for questions. An oncology dietitian will assist in discussing the impact of seeking to access experimental medicines via the “Right to Try” pathway could impact nutrition care.

Learning Objectives:

Learning Need Codes:

  • 1050 - Ethics
  • 5420 - Complementary care, alternative therapies
  • 5150 - Cancer

Kelay Trentham, MS, RDN, CSO, LMT, CD


Send Email for Kelay Trentham

Alison Bateman-House, PhD, MPH

Alison Bateman-House, PhD, MPH is an assistant professor in the Division of Medical Ethics at NYU Langone Health's School of Medicine. She is co-chair of the Working Group on Compassionate Use and Pre-Approval Access (CUPA), an interdisciplinary body that studies access to investigational drugs. Bateman-House serves as chair of the NYU/Janssen Compassionate Use Advisory Committees for Infectious Diseases and NeuroPsychology. She attended the University of Virginia for her BA and master’s of bioethics degrees and Columbia University for her MPH and PhD degrees. She served in the Peace Corps in Cote d’Ivoire; led a team of public health researchers in Louisiana after hurricanes Katrina and Rita; and was “embedded” in the Johns Hopkins Oncology Center, investigating terminally ill patients' knowledge and understanding of clinical research. She has written and spoken frequently on the history and ethics of using humans as research subjects, on clinical trial accessibility, and on pre-approval access to new medical treatments.


Send Email for Alison Bateman-House


159. Right-to-Try and Experimental Drugs: What Every Health Professional Needs to Know

MP3 Handouts Video

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for 159. Right-to-Try and Experimental Drugs: What Every Health Professional Needs to Know